The New Frontier of Immuno-Oncology

Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.

About Pionyr Immunotherapeutics

The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.

Learn More

Our Science

Pionyr’s Myeloid TuningTM technology builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.

Learn More

Pionyr Pipeline

Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, have been cleared by the FDA to initiate clinical trials.

Program (Target)
PY314 (TREM2) / Depletion
PY159 (TREM1) / Repolarization
PY265 / Immune Actuation
PI-115 / Antigen Presentation
TME Targeting

Become a Pionyr

Pionyr Immunotherapeutics is currently seeking individuals with myeloid biology, immunology, assay development, in vivo pharmacology, DMPK, or translational science expertise to help advance our lead programs into clinical testing.

Learn More

Upcoming Events

September 27-30, 2021
Discovery on Target, Virtual & Boston, MA
Pionyr Presentation

September 27 - October 1, 2021
15th WRIB, Virtual & Orlando, FL
Pionyr Poster Presentations

September 28-30, 2021
Macrophage-Directed Therapies Summit, Virtual
Pionyr Presentations

October 7-10, 2021
Pionyr Poster Presentation

October 8-9, 2021
8th Immunotherapy of Cancer Conference (ITOC8), Virtual 
Pionyr Poster Presentation

Recent News

June 22, 2021
Pionyr and Abcam Extend Partnership to Evaluate TREM2-Expressing Cells in Cancer Patients

March 29, 2021
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development

November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

More News

Contact Us

Pionyr Immunotherapeutics Inc.
2 Tower Pl, Suite 800
South San Francisco, CA 94080
(650) 825-6140